EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)Open Access · CC BY-NC-ND 4.0

Efficacy and safety of inclisiran monotherapy in Chinese adults with elevated low-density lipoprotein cholesterol: Results from the VICTORION-Mono China trial

Yong Huo, Janna Sand Dejmek, Zuyi Yuan, Daoquan Peng, Jorge Mena-Madrazo, Karen X Liu, Mengli Zhang, Yuan Ji, Xiaochun Xing, Zhuhua Yao, Yuyang Liu, Weihong Jiang und 1 weitere

Journal of Clinical Lipidology · 2026-09 · 20 (9) · 1909-1920

DOI: 10.1016/j.jacl.2026.06.016 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Lipidology, 2026-09. Verfasst von Yong Huo und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Peking University First Hospital, Beijing, China (Huo). Electronic address: huoyong@263.net.cn. Hauptthemen laut MEDLINE: Cholesterol, LDL, RNA, Small Interfering. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novartis Pharma AG.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of death in China. Elevated low-density lipoprotein cholesterol (LDL-C) is a major, modifiable cardiovascular disease and mortality risk factor, but many patients fail to achieve guideline-recommended lipid goals. Although inclisiran provides sustained and effective LDL-C reductions alone or when combined with lipid-lowering therapies (LLTs), its effectiveness as monotherapy has not been investigated in patients from China. OBJECTIVE: To evaluate the efficacy and safety of inclisiran monotherapy in Chinese adults with low/moderate ASCVD risk and elevated LDL-C not receiving LLT. METHODS: VICTORION-Mono China (NCT05888103) was a phase 3, multicenter, randomized trial, comprising a double-blind, placebo-controlled, 6-month treatment period, and a 6-month open-label extension period. The primary endpoint was the percentage change in LDL-C from baseline to Day 150. Other lipid biomarkers and safety were also assessed. RESULTS: In 207 randomized patients, inclisiran significantly reduced LDL-C vs placebo on Day 150 (least squares mean [LSM] difference: -47.50%; P < 0.0001), with reductions sustained through Day 360. Furthermore, on Day 150, inclisiran induced a significant (P < 0.0001) reduction in other atherogenic lipoproteins and lipid biomarkers (placebo-adjusted LSM difference: lipoprotein(a), -30.27%; nonhigh-density lipoprotein cholesterol, -40.57%; apolipoprotein B, -36.84%). Inclisiran was well-tolerated; the most common drug-related treatment-emergent adverse events were mild hepatic enzyme elevations, injection-site reactions, and nausea. CONCLUSION: Inclisiran monotherapy provided sustained and effective LDL-C reductions with a favorable safety profile in Chinese adults with low/moderate ASCVD risk. These findings align with previous observations in statin-treated patients, supporting inclisiran monotherapy as a potential LDL-C-lowering option for Chinese patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cholesterol, LDLRNA, Small InterferingAdultAgedFemaleHumansMaleMiddle AgedChinaDouble-Blind MethodTreatment OutcomeEast Asian People

Stichwörter der Autor:innen

Cardiovascular riskChinese adultsClinical trialInclisiranLow-density lipoprotein cholesterolMonotherapyPhase 3

Substanzen

ALN-PCSCholesterol, LDLRNA, Small Interfering

Autor:innen und Institutionen

  • Department of Cardiology, Peking University First Hospital, Beijing, China (Huo). Electronic address: huoyong@263.net.cn.
  • Novartis Pharma AG, Basel, Switzerland (Dejmek, Mena-Madrazo, and Liu).
  • Department of Cardiovascular Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China (Yuan).
  • Department of Cardiovascular Medicine, The Second Xiangya Hospital of Central South University, Changsha, China (Peng).
  • China Novartis Institutes for Biomedical Research Co Ltd, Shanghai, China (Zhang and Bai).
  • Department of Cardiology, Changzhou No.2 People's Hospital, Changzhou, China (Ji).

Förderung

  • Novartis Pharma AG

Zitieren

APA

Huo, Y., Dejmek, J. S., Yuan, Z., Peng, D., Mena-Madrazo, J., Liu, K. X., Zhang, M., Ji, Y., Xing, X., Yao, Z., Liu, Y., Jiang, W., & Bai, L. (2026). Efficacy and safety of inclisiran monotherapy in Chinese adults with elevated low-density lipoprotein cholesterol: Results from the VICTORION-Mono China trial. Journal of Clinical Lipidology, 20(9), 1909-1920. https://doi.org/10.1016/j.jacl.2026.06.016

Vancouver

Huo Y, Dejmek JS, Yuan Z, Peng D, Mena-Madrazo J, Liu KX, et al. Efficacy and safety of inclisiran monotherapy in Chinese adults with elevated low-density lipoprotein cholesterol: Results from the VICTORION-Mono China trial. Journal of Clinical Lipidology. 2026;20(9):1909-1920. doi:10.1016/j.jacl.2026.06.016

BibTeX
@article{Huo2026,
  author = {Huo, Yong and Dejmek, Janna Sand and Yuan, Zuyi and Peng, Daoquan and Mena-Madrazo, Jorge and Liu, Karen X and Zhang, Mengli and Ji, Yuan and Xing, Xiaochun and Yao, Zhuhua and Liu, Yuyang and Jiang, Weihong and Bai, Lingyan},
  title = {Efficacy and safety of inclisiran monotherapy in Chinese adults with elevated low-density lipoprotein cholesterol: Results from the VICTORION-Mono China trial},
  journal = {Journal of Clinical Lipidology},
  year = {2026},
  volume = {20},
  number = {9},
  pages = {1909--1920},
  doi = {10.1016/j.jacl.2026.06.016}
}
Kostenlos starten →